BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Johnson and Johnson
US Department of Justice
Daiichi Sankyo

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,270,317

« Back to Dashboard

Summary for Patent: 5,270,317

Title: N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
Abstract:The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula ##STR1## in which the substituents are as defined in the specification. Application: Angiotensin II antagonists
Inventor(s): Bernhart; Claude (Saint Gely du Fesc, FR), Breliere; Jean-Claude (Montpellier, FR), Clement; Jacques (Saussan, FR), Nisato; Dino (Saint Georges d'Orques, FR), Perreault; Pierre (Montpellier, FR), Muneaux; Claude (Les Matelles, FR), Muneaux; Yvette (Les Matelles, FR)
Assignee: Elf Sanofi (Paris, FR)
Application Number:07/794,497
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,270,317

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France90 03536Mar 20, 1990
France90 10144Sep 01, 1990
France91 11161Sep 10, 1991

International Patent Family for Patent: 5,270,317

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria167475► Subscribe
Australia2286892► Subscribe
Australia641005► Subscribe
Australia661017► Subscribe
Australia7561091► Subscribe
Canada2057913► Subscribe
Canada2077967► Subscribe
Czechoslovakia9100745► Subscribe
Czech Republic287064► Subscribe
Czech Republic287225► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: